Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

@article{Brjesson2003PhaseIT,
  title={Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.},
  author={Pontus K E B{\"o}rjesson and Ernst J. Postema and J. D. Roos and David R. Colnot and Henri August Marie Marres and Mathijs H van Schie and Gerd Stehle and Remco de Bree and Gordon B J Snow and Wim J. G. Oyen and Guus A. M. S. van Dongen},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 10 Pt 2},
  pages={3961S-72S}
}
PURPOSE In previous studies, we have shown the potential of radioimmunotherapy (RIT) with (186)Re-labeled chimeric monoclonal antibody (MAb) U36 for treatment of head and neck cancer. A limitation of this anti-CD44v6 MAb, however, appeared to be its immunogenicity, resulting in human antichimeric antibodies in 40% of the patients. Aiming for a less immunogenic anti-CD44v6 MAb, the humanized MAb BIWA 4 (bivatuzumab) was introduced. In the present Phase I RIT study, we determined the safety… CONTINUE READING
44 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…